LINC00665 is upregulated in non-small cell lung cancer and can activate the PI3K/AKT pathway by increasing the stability of EZH2, an important component of the initiation complex (PRC2), and mediates the expression of EGFR, thereby counteracting the effect of gefitinib [6]. The gene discussed is EZH2; the disease is non-small cell lung carcinoma.